Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPT-CBD
- Development stage
- Phase 2
- Lead developer
- InnoCan Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Subcutaneous
01
Overview
LPT-CBD is a specialized formulation of cannabidiol (CBD) that utilizes liposomal or nanoencapsulation technology to improve the drug's pharmacokinetic profile. Developed by companies such as Innocan Pharma and Aphios Pharma, the LPT-CBD platform (Liposome Platform Technology) is designed to provide a sustained-release delivery system, addressing the low bioavailability and rapid metabolism associated with conventional CBD administration. Innocan Pharma is advancing LPT-CBD in the preclinical stage for the treatment of epilepsy and chronic pain management, utilizing injectable liposomes to maintain therapeutic levels of CBD over extended periods. Aphios Pharma has investigated a similar nanoencapsulated CBD formulation, designated APH-1501, in clinical trials for reducing cravings in patients with opioid dependence. By encapsulating CBD within lipid-based vesicles, LPT-CBD aims to enhance the stability and targeted delivery of the cannabinoid to the central nervous system.
- Other names
- Liposomal CannabidiolNanoencapsulated Cannabidiol
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on LPT-CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPT-CBD.